Latest News

Sienna Acquires Unique Liquid Biopsy & Exosome Isolation Technology
02-Apr-2019

Sienna Acquires Unique Liquid Biopsy & Exosome Isolation Technology Sienna to a.. READ MORE

Sienna Appoints Exclusive Distribution Partner for Brazil
18-Mar-2019

Inside Diagnósticos appointed as exclusive distributor. Brazil is a major market with signif.. READ MORE

FNN coverage - CEO Interview 2019 update
13-Mar-2019

In this interview, Sienna CEO Matthew Hoskin shares an update on the Company’s progress in 2018,.. READ MORE

Investor Information

Sienna is a public listed company headquartered in Melbourne, Australia. In August 2017, Sienna listed on the Australian Securities Exchange under the ticker symbol SDX. The company is governed by an experienced board and management team. Sienna has benefited from over $6.9M in R&D Tax Incentive refunds and government grant programs, significantly bolstering investor contributions and facilitating the progress and growth to date. READ MORE

 

Research

Sienna’s core activities have historically focused on the clinical translation of biomarkers using novel diagnostic technologies for applications in pathology laboratories. The development of inexpensive, high performing in vitro diagnostic tests is expected to lead to radical changes in the approach to care and assessment of cancer patients – a change welcomed by clinicians and governments.  READ MORE

 

About Sienna

Sienna is a medical technology company focussed on the development and commercialisation of novel IVD (in vitro diagnostic) tests. Sienna manufactures IVD products for pathology laboratories to use in their menu of testing services. READ MORE

Sienna has launched its first IVD product for the detection of hTERT, and is working on expansion of the product development and commercialisation pipeline. NETs technology will play a key role in the sample preparation step for future IVD products.


– CEO, Matthew Hoskin

Contact Sienna

Sienna Cancer Diagnostics

1 Dalmore Drive Scoresby VIC 3179 Australia

Telephone +61 3 8288 2141 Facsimile +61 3 8288 2059